T. Rowe Price Investment Management Adds $401M in Kymera Therapeutics, Inc. ($KYMR)
Key Points
- T. Rowe Price Investment Management changed its Kymera Therapeutics, Inc. ($KYMR) stake by 767.8% last quarter, boosting to 5,464,997 shares worth $453.38 million.
- Wall Street's consensus rating on $KYMR is Strong Buy and an average price target of $119.43.
- $KYMR last traded around $82.96.
T. Rowe Price Investment Management increased its position in Kymera Therapeutics, Inc. ($KYMR) by 767.8% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,464,997 shares of Kymera Therapeutics, Inc. after buying 4,835,252 shares during the quarter. T. Rowe Price Investment Management's holdings in Kymera Therapeutics, Inc. were worth $453.38 million as of its most recent filing.
Kymera Therapeutics, Inc. ($KYMR) Stock
Kymera Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.